Advertisement

Studi farmacoeconomici: aspetti metodologici

Chapter
  • 199 Downloads
Part of the Aspetti psico-sociali della sclerosi multipla book series (APSSM, volume 4)

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Bibliografia

  1. 1.
    Holloway RG (1996) Cost-effectiveness analysis: what is it and how will it influence neurology. Ann Neurol 39(6): 818–823PubMedCrossRefGoogle Scholar
  2. 2.
    Newby D, Hill S (2003) Use of pharmacoeconomics in prescribing research. Part 2: cost-minimization analysis—when are two therapies equal? J Clin Pharm Ther 28(2):145–150PubMedCrossRefGoogle Scholar
  3. 3.
    Lopert R, Lang DL, Hill SR (2003) Use of pharmacoeconomics in prescribing research. Part 3: Cost-effectiveness analysis—a technique for decision-making at the margin. J Clin Pharm Ther 28(3):243–249PubMedCrossRefGoogle Scholar
  4. 4.
    Brinsmead R, Hill S (2003) Use of pharmacoeconomics in prescribing research. Part 4: is cost-utility analysis a useful tool? J Clin Pharm Ther 28(4):339–346PubMedCrossRefGoogle Scholar
  5. 5.
    EuroQol Group (1990) EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 16:199–208Google Scholar
  6. 6.
    Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30(6):473–483PubMedGoogle Scholar
  7. 7.
    Lang DL, Lopert R, Hill SR (2003) Use of pharmacoeconomics in prescribing research. Part 5: modelling — beyond clinical trials. J Clin Pharm Ther 28(5):433–439PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2005

Authors and Affiliations

There are no affiliations available

Personalised recommendations